Categories Analysis, Health Care

Alexion Pharmaceuticals could still be a valuable addition to your portfolio

Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover target for Amgen Inc (NASDAQ: AMGN), but the latter snubbed Alexion at the last minute and instead picked Celgene’s (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.

This came as a huge jolt for Alexion investors, who were hoping to see big gains post the acquisition. ALXN stock, meanwhile, plunged following the announcement of the deal with Celgene.

pharma stocks
Image for representation (Photo by Drew Hays on Unsplash)

Things took an even worse turn for Alexion when ally-turned-foe Amgen challenged three of its patents relating to its flagship drug Soliris. Soliris is a drug used in the treatment of rare diseases and accounts for almost 90% of its total sales.

The US Patent and Trademark Office (PTO) will review these patents and if they fall, Amgen will have the chance to launch biosimilars of this drug, which have been under development for some time.

In spite of these headwinds, Alexion could be a valuable addition to your portfolio, given the headstart it has achieved in rare diseases. Soliris is a best-selling drug not because of more sales, but mostly due to its high price tag. In the first half of 2019, Soliris revenues came in at around $2 billion.

READ: Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion

The high price tag also ensures Alexion has a net margin of about 29.60%, suggesting it is more profitable than most of its peers. High institutional ownership makes the stock stable and focused as well.

Even though Alexion has missed out on sealing a deal with Amgen, the company’s progress with rare diseases continues to make it a good takeover target. Novartis (NYSE: NVS), Pfizer (NYSE: PFE) and Roche could be the companies that may forge a deal with Alexion sometime in the future.

alexion pharma

The continued prospects of a takeover and cheap valuation spurred by the recent turn of events make ALXN an attractive option that could be considered in the biotech space.

DISCLAIMER: The article does not necessarily imply the views of AlphaStreet, and contains opinions of the author alone. 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top